Multiple Myeloma Management

Multiple Myeloma Management icon

ASO Keyword Dashboard

Tracking 17 keywords for Multiple Myeloma Management in Apple App Store

Developer: Med Learning Group Category: medical

Multiple Myeloma Management tracks 17 keywords (1 keyword ranks; 16 need traction). Key metrics: 0% top-10 coverage, opportunity 43.7, difficulty 31.9, best rank 68.

Tracked keywords

17

1  ranked •  16  not ranking yet

Top 10 coverage

0%

Best rank 68 • Latest leader 88

Avg opportunity

43.7

Top keyword: multiple

Avg difficulty

31.9

Lower scores indicate easier wins

Opportunity leaders

  • multiple

    Opportunity: 58.0 • Difficulty: 54.5 • Rank 88

    Competitors: 550

    78.1
  • management

    Opportunity: 58.0 • Difficulty: 46.0 • Rank —

    Competitors: 138

    66.3
  • important

    Opportunity: 58.0 • Difficulty: 51.6 • Rank —

    Competitors: 248

    70.0
  • data

    Opportunity: 58.0 • Difficulty: 54.6 • Rank —

    Competitors: 472

    76.8
  • well

    Opportunity: 58.0 • Difficulty: 49.3 • Rank —

    Competitors: 296

    72.1

Unranked opportunities

  • management

    Opportunity: 58.0 • Difficulty: 46.0 • Competitors: 138

  • important

    Opportunity: 58.0 • Difficulty: 51.6 • Competitors: 248

  • data

    Opportunity: 58.0 • Difficulty: 54.6 • Competitors: 472

  • well

    Opportunity: 58.0 • Difficulty: 49.3 • Competitors: 296

  • trials

    Opportunity: 57.0 • Difficulty: 26.7 • Competitors: 10

High competition keywords

  • multiple

    Total apps: 2,846 • Major competitors: 550

    Latest rank: 88 • Difficulty: 54.5

  • data

    Total apps: 2,494 • Major competitors: 472

    Latest rank: — • Difficulty: 54.6

  • well

    Total apps: 1,543 • Major competitors: 296

    Latest rank: — • Difficulty: 49.3

  • important

    Total apps: 1,244 • Major competitors: 248

    Latest rank: — • Difficulty: 51.6

  • management

    Total apps: 856 • Major competitors: 138

    Latest rank: — • Difficulty: 46.0

All tracked keywords

Includes opportunity, difficulty, rankings and competitor benchmarks

Major Competitors
multiple581005478

2,846 competing apps

Median installs: 239,425

Avg rating: 4.6

8868

550

major competitor apps

management581004666

856 competing apps

Median installs: 221,550

Avg rating: 4.6

138

major competitor apps

important581005270

1,244 competing apps

Median installs: 231,362

Avg rating: 4.6

248

major competitor apps

trials571002741

65 competing apps

Median installs: 299,450

Avg rating: 4.6

10

major competitor apps

data581005577

2,494 competing apps

Median installs: 237,338

Avg rating: 4.6

472

major competitor apps

well581004972

1,543 competing apps

Median installs: 241,700

Avg rating: 4.6

296

major competitor apps

considering561002434

30 competing apps

Median installs: 216,950

Avg rating: 4.6

7

major competitor apps

clinical571003445

97 competing apps

Median installs: 156,075

Avg rating: 4.7

13

major competitor apps

preliminary0411418

5 competing apps

Median installs: 93,250

Avg rating: 4.7

1

major competitor apps

mechanism561002031

23 competing apps

Median installs: 150,500

Avg rating: 4.6

2

major competitor apps

approved571004253

229 competing apps

Median installs: 250,250

Avg rating: 4.7

47

major competitor apps

novel571002842

68 competing apps

Median installs: 217,088

Avg rating: 4.7

12

major competitor apps

agents571003343

75 competing apps

Median installs: 299,450

Avg rating: 4.7

18

major competitor apps

recognizing561002231

23 competing apps

Median installs: 162,125

Avg rating: 4.6

4

major competitor apps

implementing018711

2 competing apps

Median installs: 140,662

Avg rating: 4.6

0

major competitor apps

clinical trials0341116

4 competing apps

Median installs: 281,625

Avg rating: 4.8

0

major competitor apps

efficacy0412518

5 competing apps

Median installs: 250,825

Avg rating: 4.6

1

major competitor apps

17 keywords
1 of 1

App Description

Bispecific antibodies are a novel mechanism in the management in the relapsed/refractory multiple myeloma. Recognizing the mechanism of these agents as well as preliminary efficacy data is important in considering clinical trials and implementing approved bispecific antibodies in the management of multiple myeloma.